ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OPKO Health, Inc.; Transition Therapeutics Ireland Limited
• Collaborator: Transition Therapeutics
• Treatments: Inositol

Criteria

Inclusion Criteria:

• This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.

Exclusion Criteria:

• Subject has no new medical contraindications to continued participation in the study.